Platelet transfusion,
does it really help with Reduced death or dependence at three months?
research showsThe grade is D with 34 points. PATCH randomized 190 patients to added platelet transfusion, 97, or standard care, 93, and analyzed everyone with no three-month loss to follow-up. The modified Rankin distribution for death or dependence was worse with transfusion, adjusted common odds ratio 2.05 (95% CI 1.18 to 3.56; P=.0114). One trial is not repeated refutation, but its significant result ran opposite to the benefit claim, giving D.
ads claimTaking an antiplatelet drug does not mean that routine platelet replacement improves function after hemorrhage; PATCH found the opposite. This verdict is limited to routine transfusion for acute spontaneous intracerebral hemorrhage when surgery is not planned.
Useful facts when choosing a product
- PATCH is registered as NTR1303.
- The trial was open label, but three-month outcome assessors and analysts were masked.
- In-hospital serious adverse events occurred in 42% with transfusion versus 29% with standard care.
What the research actually shows
PATCH was an open-label, masked-endpoint randomized trial at 60 hospitals. A secure web-based system concealed allocation and used biased-coin randomization. Participants and local investigators delivering treatment knew assignment, but outcome assessors and data analysts did not. All 190 participants completed three-month follow-up and were analyzed by assigned group. Because death and dependence were assessed under masking, open treatment itself was not counted as a limitation; total enrollment below 200 was counted as one limitation. Funding came from public and nonprofit sources including the Netherlands Organisation for Health Research and Development, Sanquin Blood Bank, the French Ministry of Health, Chest Heart and Stroke Scotland, and UK MRC fellowships.
Why this is classified as D (34)
A publicly and noncommercially funded randomized trial found significant worsening of a direct clinical outcome, but it was one 190-patient confirmatory trial, giving D with 34 points.
Counterpoint. Thrombocytopenia, traumatic brain hemorrhage, and emergency surgery differ from the narrow PATCH population.
Rejudgment record. Cross-check applied — Cross-checked the Lancet PATCH report, protocol, prespecified analysis plan, and NTR1303 for population, secure web allocation, masked outcome assessment, complete analysis, funding, and harms
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E- | Harm increased in the trials |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced death or dependence at three months | D | The ordinal outcome was significantly worse with transfusion. |
| Transfusion for emergency surgery, trauma, or thrombocytopenia | ? | These settings were outside PATCH and were not pooled into this verdict. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Open-label randomized trial with masked endpoints at 60 hospitals | 93 | Netherlands Organisation for Health Research and Development, Sanquin Blood Bank, French Ministry of Health, Chest Heart and Stroke Scotland, MRC, and related public or nonprofit sources | Three-month modified Rankin ordinal shift for death or dependence | Worse with transfusion: adjusted common OR 2.05 (95% CI 1.18 to 3.56); serious adverse events 42% versus 29%; in-hospital death 24% versus 17% | Publicly and noncommercially funded trial showing harm on a direct clinical outcome |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Platelet transfusion x antiplatelet-associated spontaneous intracerebral hemorrhage — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/platelet-transfusion-antiplatelet-associated-spontaneous-intracerebral-hemorrhage/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.